Reed-Sternberg–Like Cells in Non-Hodgkin Lymphomas
نویسندگان
چکیده
منابع مشابه
Radioimmunotherapy of non-Hodgkin lymphomas.
Enthusiasm for the use of monoclonal antibodies, such as rituximab, has markedly changed the approach to patients with non-Hodgkin lymphomas (NHLs). Nevertheless, more effective therapies are needed. Radioimmunotherapy as a form of targeted radiation therapy may add significantly to our therapeutic options. Yttrium Y 90 ibritumomab tiuxetan, recently approved by the Food and Drug Administration...
متن کاملSilencing of the p18 gene by promoter hypermethylation in the Reed-Sternberg cells in Hodgkin Lymphomas
p18 is a cyclin-dependent kinase inhibitor that interferes with the Rb-kinase activity of CDK6/CDK4. Disruption of p18 in mice impairs B-cell terminal differentiation and confers increased susceptibility to tumor development; however, alterations of p18 in human tumors have rarely been described. We used a tissue-microarray approach to analyze p18 expression in 316 Hodgkin Lymphomas (HL). Nearl...
متن کاملParaneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas.
Paraneoplastic neurological syndromes (PNSs) rarely associate with Hodgkin lymphoma (HL) and non-HLs (NHLs). Except for paraneoplastic cerebellar degeneration (PCD) in HL and dermato/ polymyositis in both HL and NHL, other PNSs are uncommon and have only been reported as isolated case reports or short series. There are several important differences in PNSs when occurring in association with HL ...
متن کاملShifting Treatment Paradigms in Non-hodgkin Lymphomas
Disclosure: Prof Caballero has served as a member of advisory boards and participated in educational activities for Bristol-Myers Squibb, Celgene, Janssen, Kite, Nordic, and Roche. Prof Vitolo has received research grants and served as principal investigator in studies sponsored by Celgene and Roche; he received sponsorship for speaking engagements at conferences and educational activities from...
متن کاملGene expression profiling in non-Hodgkin lymphomas.
Although the current WHO classification (Swerdlow et al. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon, 2008 [1]) for hematolymphoid neoplasms has delineated lymphomas based on the combined morphologic, immunophenotypic, and genotypic findings, further refinement is necessary especially in regard to therapeutics and progn...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Pathology & Laboratory Medicine
سال: 2015
ISSN: 1543-2165,0003-9985
DOI: 10.5858/arpa.2015-0197-rai